8-K
filed May 18, 2026, 9:33 AM ET
ticker QNCX
CIK 0001662774
M&A
confidence high
sentiment neutral
materiality 1.00
Quince Therapeutics, Inc. (QNCX): M&A transaction — Quince acquires Orphai in reverse merger; raises $115M PIPE; appoints Dr. Roberts
Quince Therapeutics, Inc.
- Acquisition closed May 18; Quince issued 3.26M shares and 67K Series C Preferred to Orphai holders.
- Pre-transaction Quince holders will own ~6.9% post-financing; new Investors hold ~61.2%.
- PIPE of $115M via sale of Series C Preferred and warrants; warrants could add ~$72M.
- Dr. Brigette Roberts appointed to Board and as Chief of Corporate Affairs; salary $600K.
- Retention bonuses of $700K for CEO Dirk Thye and $500K for COO Brendan Hannah, contingent on stockholder approval.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Brigette Roberts was appointed as Director at Quince Therapeutics, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Brigette Roberts, M.D., was appointed to the Board as a Class III director.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Brigette Roberts was appointed as Chief of Corporate Affairs at Quince Therapeutics, Inc..
- Action
- appointed
- Role
- Chief of Corporate Affairs
Exact text from the filing
Dr. Roberts was also appointed as the Chief of Corporate Affairs of the Company.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Quince Therapeutics, Inc.: Filed Certificate of Designation creating Series C Preferred Stock (effective 2026-05-18).
- Change
- charter amendment
- Effective
- 2026-05-18
Exact text from the filing
On May 18, 2026, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock (the " Certificate of Designation ") in connection with the Acquisition and the Financing referenced in Item 1.01 above.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Quince Therapeutics, Inc. completed an acquisition involving Orphai Therapeutics, LLC and Orphai Holdings Therapeutics, Inc. (closed 2026-05-18).
- Action
- acquisition
- Counterparty
- Orphai Therapeutics, LLC and Orphai Holdings Therapeutics, Inc.
- Closing
- 2026-05-18
Exact text from the filing
On May 18, 2026, the Company completed its acquisition of the Orphai Entities.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.